Potential for modern dosage forms of azithromycin in the treatment of chlamydial infection in women: An expert opinion from dermatovenerologist and medical lawyer
https://doi.org/10.21518/ms2026-118
Abstract
Chlamydia trachomatis is the most common bacterial sexually transmitted infection (STI) worldwide. In 2012, the prevalence of urogenital chlamydial infection (UGCI) among women was 4.2%. According to 2020 data released by the World Health Organization (WHO), approximately 129 million new C. trachomatis infections are reported annually worldwide. It should be noted that in the Russian Federation, in 2021, the incidence rate of UGCI was 17.8 per 100,000 population, which is 27.6 times lower than the official incidence rate in the United States (490.6 per 100,000 population) for the same period. Untreated UGHI can lead to pelvic inflammatory diseases (PID), as well as cervicitis and endometritis, which have a tendency for transformation into chronicity. UGHI is associated with spontaneous abortion, chorioamnionitis, premature rupture of membranes, ectopic pregnancy, preterm labor, and stillbirth. Furthermore, chlamydia increases the risk of infertility in both men and women. The authors note that the failure to screen women with complicated gynecological/obstetric anamnesis for sexually transmitted infections (STIs) at the pregravid preparation stage may subsequently cause the diagnosis of a perinatal infection with an unidentified pathogen. Pregnant women with UGCI are treated at any gestation stage using systemic antibacterial agents with due account for their effects on the fetus. Currently, azithromycin is the best option for the treatment of UGCI during pregnancy. This article reviews current clinical guidelines and other legal acts applicable to the diagnosis and treatment of chlamydial infection in women.
About the Authors
A. A. Khryanin
Novosibirsk State Medical University;
Association of Obstetricians-Gynecologists and Dermatovenerologists;
Territorial Fund of Mandatory Medical Insurance
Russian Federation
Russian Federation
Aleksey A. Khryanin, Dr. Sci. (Med.), Professor of the Department of Dermatovenereology and Cosmetology; President; Expert in Medical Care Quality
52, Krasny Ave., Novosibirsk, 630091, Russia
55, Lenin St., Novosibirsk, 630004, Russia
42A, Krasny Ave., Novosibirsk, 630099, Russia
M. V. Radchenko
South Ural State University (National Research University);
South Ural State Medical University
Russian Federation
Russian Federation
Margarita V. Radchenko,Cand. Sci. (Law), Associate Professor of the Department of Civil Law and Civil Procedure, Law Institute; Associate Professor of the Department of Public Health and Healthcare, Institute of Continuing Professional Education
76, Lenin Ave., Chelyabinsk, 454080, Russia
64, Vorovskiy St., Chelyabinsk, 454092, Russia;
References
1. Li C, Ong J, Tang W, Wang C. Chlamydia trachomatis infection: Epidemiology, prevention, clinical, and basic science research. Front Public Health. 2024;12:1467902. https://doi.org/10.3389/fpubh.2024.1467902.
2. Gottlieb SL, Spielman E, Abu-Raddad L, Aderoba AK, Bachmann LH, Blondeel K et al. WHO global research priorities for sexually transmitted infections. Lancet Glob Health. 2024;12(9):e1544–e1551. https://doi.org/10.1016/S2214-109X(24)00266-3.
3. Workowski KA, Bachmann LH, Chan PА, Johnston CM, Muzny CA, Park I et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. https://doi.org/10.15585/mmwr.rr7004a1.
4. Tang W, Mao J, Li KT, Walker JS, Chou R, Fu R et al. Pregnancy and fertilityrelated adverse outcomes associated with Chlamydia trachomatis infection: a global systematic review and meta-analysis. Sex Transm Infect. 2020;96(5):322–329. https://doi.org/10.1136/sextrans-2019-053999.
5. Low N, Redmond S, Uusküla A, van Bergen J, Ward H, Andersen B, Götz H. Screening for genital chlamydia infection. Cochrane Database Syst Rev. 2016;(9):CD010866. https://doi.org/10.1002/14651858.CD010866.pub2.
6. Krasnoselskikh TV, Sokolovskiy EV, Rakhmatulina MR, Novoselova EYu, Melekhina LE. Syphilis and some other STIs in the Russian Federation: past, present and ways to control of the epidemiological situation in the future. Vestnik Dermatologii i Venerologii. 2023;99(4):41–59. (In Russ.) https://doi.org/10.25208/vdv13726.
7. Rahangdale L, Guerry S, Bauer HM, Packel L, Rhew M, Baxter R et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex Transm Dis. 2006;33(2):106–110. https://doi.org/10.1097/01.olq.0000187226.32145.ea.
8. Brocklehurst P, Rooney G. Interventions for treating genital chlamydia trachomatis infection in pregnancy. Cochrane Database Syst Rev. 1998;(4):CD000054. https://doi.org/10.1002/14651858.CD000054.
9. Darville T. Chlamydia trachomatis infections in neonates and young children. Semin Pediatr Infect Dis. 2005;16(4):235–244. https://doi.org/10.1053/j.spid.2005.06.004.
10. Wang Y, Yang WB, Yuan HY, Zhang QX, Zhu XY. Analysis of the infection status and the drug resistance of mycoplasma and chlamydiae in genitourinary tracts of children with suspected nongonococcal urethritis. Zhonghua Er Ke Za Zhi. 2009;47(1):62–64. (In Chinese) https://doi.org/10.3760/cma.j.issn.0578-1310.2009.01.015.
11. Балашова ЕН, Белоусова ТВ, Бем ЕВ, Зеленкин НМ, Иванов ДО, Извекова ИЯ и др. Инфекция, специфичная для перинатального периода: клинические рекомендации. М.; 2025. 70 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/978_1.
12. Адамян ЛВ, Андреева ЕН, Артымук НВ, Белокринницкая ТЕ, Беженарь ВФ, Струнина ЛВ и др. Воспалительные болезни женских тазовых органов: клинические рекомендации. М.; 2024. 49 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/643_2.
13. Адамян ЛВ, Артымук НВ, Беженарь ВФ, Белокринницкая ТЕ, Доброхотова ЮЭ, Киселев СИ и др. Внематочная (эктопическая) беременность: клинические рекомендации. М.; 2024. 60 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/642_2.
14. Кубанов АА, Серов ВН, Рахматулина МР, Аполихина ИА, Гомберг МА, Горбунова ЕА и др. Хламидийная инфекция: клинические рекомендации. М.; 2024. 42 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/194_2.
15. Кубанов АА, Серов ВН, Рахматулина МР, Аполихина ИА, Гомберг МА, Горбунова ЕА и др. Урогенитальные заболевания, вызванные Mycoplasma genitalium: клинические рекомендации. М.; 2024. 34 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/216_2.
16. Потекаев НН, Гомберг МА, Ахвледиани НД, Гущин АЕ, Доля ОВ, Жукова ОВ и др. Баланопостит: клинические рекомендации. М.; 2025. 43 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/928_1.
17. Потекаев НН, Гомберг МА, Ахвледиани НД, Гущин АЕ, Доля ОВ, Жукова ОВ и др. Негонококковый (неспецифический) уретрит у мужчин: клинические рекомендации. М.; 2024. 46 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/796_1.
18. Долгушина НВ, Корсак ВС, Корнеева ИЕ, Гзгзян АМ, Исакова ЭВ, Калинина ЕА и др. Женское бесплодие: клинические рекомендации. М.; 2024. 91 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/641_2.
19. White JF, Dukers-Muijrers NH, Hoebe CJ, Kenyon CR, Dc Ross J, Unemo M. 2025 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS. 2025;36(6):434–449. https://doi.org/10.1177/09564624251323678.
20. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital Chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. 2002;29(9):497–502. https://doi.org/10.1097/00007435-200209000-00001.
21. Kong FY, Tabrizi SN, Fairley CK, Vodstrcil LA, Huston WM, Chen M et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(5):1290–1297. https://doi.org/10.1093/jac/dku574.
22. Dukers-Muijrers NH, Wolffs FG, de Vries H, Götz HM, Heijman T, Bruisten S et al. Treatment Effectiveness of Azithromycin and Doxycycline in Uncomplicated Rectal and Vaginal Chlamydia trachomatis Infections in Women: A Multicenter Observational Study (FemCure). Clin Infect Dis. 2019;69(11):1946–1954. https://doi.org/10.1093/cid/ciz050.
23. Zyryanov SK, Baibulatova EA. The Use of New Dosage Forms of Antibiotics as a Way to Improve the Effectiveness and Safety of Antibiotic Therapy. Antibiotiki i Khimioterapiya. 2019;64(3-4):81–91. (In Russ.) Available at: https://www.antibiotics-chemotherapy.ru/jour/article/view/132.
24. Андреев АВ, Балашова АИ, Ванюков ПД, Гюльбасарова ЕВ, Королева АГ, Новоселова ЛА. Путеводитель по судебной практике. Патентование и оборот лекарственных средств в Российской Федерации. М.: Проспект; 2023. 336 с.
25. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2007;30(3):213–221. https://doi.org/10.1016/j.ijantimicag.2007.04.015.
26. Khryanin AA. Urogenital chlamydia infection in women: patient management tactics according to present-day foreign and Russian recommendations. Vestnik Dermatologii i Venerologii. 2015;91(2):101–110. (In Russ.) https://doi.org/10.25208/0042-4609-2015-91-2-101-110.
27. Khryanin AA, Radchenko MV. Prevention of medical malpractices in the pregnancy management with STIs: expert opinion of a medical lawyer and a dermatovenerologist (interdisciplinary discussion). Russian Journal of Woman and Child Health. 2024;7(3):259–265 (In Russ.) https://doi.org/10.32364/2618-8430-2024-7-3-7.
28. Кубанов АА, Серов ВН, Аполихина ИА, Богданова ЕВ, Гомберг МА, Гущин ЕА и др. Хламидийная инфекция: клинические рекомендации. М.; 2021. Режим доступа: https://diseases.medelement.com/disease/хламидийная-инфекция-кр-рф-2021/17419.
Review
For citations:
Khryanin AA, Radchenko MV. Potential for modern dosage forms of azithromycin in the treatment of chlamydial infection in women: An expert opinion from dermatovenerologist and medical lawyer. Meditsinskiy sovet = Medical Council. 2026;(4):96-103. (In Russ.) https://doi.org/10.21518/ms2026-118
Views:
202
JATS XML
Email this article 